Research ArticleNuclear Oncology
Radioimmunodetection of Medullary Thyroid Carcinoma Using Indium-111 Bivalent Hapten and Anti-CEA × Anti-DTPA-Indium Bispecific Antibody
J. Barbet, P. Peltier, S. Bardet, J.P. Vuillez, I. Bachelot, S. Denet, P. Olivier, F. Leccia, B. Corcuff, D. Huglo, C. Proye, E.P.Meyer Rouvier and J.F. Chatal
Journal of Nuclear Medicine July 1998, 39 (7) 1172-1178;
J. Barbet
P. Peltier
S. Bardet
J.P. Vuillez
I. Bachelot
S. Denet
P. Olivier
F. Leccia
B. Corcuff
D. Huglo
C. Proye
E.P.Meyer Rouvier
This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Radioimmunodetection of Medullary Thyroid Carcinoma Using Indium-111 Bivalent Hapten and Anti-CEA × Anti-DTPA-Indium Bispecific Antibody
J. Barbet, P. Peltier, S. Bardet, J.P. Vuillez, I. Bachelot, S. Denet, P. Olivier, F. Leccia, B. Corcuff, D. Huglo, C. Proye, E.P.Meyer Rouvier, J.F. Chatal
Journal of Nuclear Medicine Jul 1998, 39 (7) 1172-1178;
Radioimmunodetection of Medullary Thyroid Carcinoma Using Indium-111 Bivalent Hapten and Anti-CEA × Anti-DTPA-Indium Bispecific Antibody
J. Barbet, P. Peltier, S. Bardet, J.P. Vuillez, I. Bachelot, S. Denet, P. Olivier, F. Leccia, B. Corcuff, D. Huglo, C. Proye, E.P.Meyer Rouvier, J.F. Chatal
Journal of Nuclear Medicine Jul 1998, 39 (7) 1172-1178;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Pretargeting: A Path Forward for Radioimmunotherapy
- Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis
- Current Landscape in Clinical Pretargeted Radioimmunoimaging and Therapy
- Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study
- Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
- Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial
- Quantitative Immuno-SPECT Monitoring of Pretargeted Radioimmunotherapy with a Bispecific Antibody in an Intraperitoneal Nude Mouse Model of Human Colon Cancer
- Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement
- In Reply
- Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy
- Improved Targeting of Pancreatic Cancer: Experimental Studies of a New Bispecific Antibody, Pretargeting Enhancement System for Immunoscintigraphy
- Pretargeted {alpha} Emitting Radioimmunotherapy Using 213Bi 1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-Tetraacetic Acid-Biotin
- In Vivo Evaluation of Pretargeted 64Cu for Tumor Imaging and Therapy
- Pretargeted Radioimmunotherapy of Cancer: Progress Step by Step
- Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha -emitting radionuclide, bismuth 213
- Immunoscintigraphy with Positron Emission Tomography: Gallium-68 Chelate Imaging of Breast Cancer Pretargeted with Bispecific Anti-MUC1/Anti-Ga Chelate Antibodies
- Successful Surgical Removal of Occult Metastases of Medullary Thyroid Carcinoma Recurrences with the Help of Immunoscintigraphy and Radioimmunoguided Surgery